For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

GPs are free to prescribe semaglutide to all eligible patients in line with NICE guidelines after long-term shortages have ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

The FDA said to stop all use of Philips' Tack Endovascular System, which is under class I recall for user difficulties in ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Trulicity (dulaglutide) is not a weight loss drug, but people receiving it may lose weight. Higher doses of Trulicity typically result in more weight loss. The FDA has not approved Trulicity as a ...

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...